For the Fifth Time in Six Years, the Bioanalytical Laboratory Earns an Exclusive Ranking
AUGUST 15, 2018—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has been named to Inc. Magazine’s Inc. 5000 list of the fastest-growing private companies in America for 2018. This esteemed list recognizes groundbreaking private, for-profit, and independent companies that have achieved significant percentage growth of annual revenue over the last three years (2015 – 2017). BioAgilytix came in at #1833 on this year’s list, jumping 1,713 spots from its ranking the previous year, and placing the company among some of the most innovative entrepreneurial businesses in the country.
This milestone marks the fifth time in six years that BioAgilytix has been recognized by Inc. 5000 for its strong growth. In addition to earning a spot on the list just last year in 2017, BioAgilytix was also ranked in 2013, 2014, and 2016, putting the organization in exclusive company. Out of the nearly seven million private companies in the United States, only a small fraction have demonstrated the level of consistent, sustained high growth that BioAgilytix has achieved, and of the tens of thousands that apply to the Inc. 5000 list, only one in ten have been ranked five times. In a constantly evolving, highly innovative field, the multiple rankings prove that BioAgilytix remains on the leading edge of large molecule bioanalytical testing and is successfully meeting increased customer demands for preclinical, clinical, and manufacturing support for immunogenicity, pharmacokinetic, cell-based assay, and biomarker studies.
“We are honored and proud to be named to the Inc. 5000 list for a fifth time. Such a small percentage of applicants earn a spot on this list at all, so I am thrilled that the unique achievements of BioAgilytix’s team are once again being recognized. Our consistent growth is truly a reflection of the dedication of our employees and the value-add partnerships they forge to continually meet and exceed the expectations of our pharmaceutical and biotechnology customers,” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “Since our founding ten years ago, we have endeavored to help our customers successfully navigate the inherent complexities of large molecule bioanalysis so that they can bring life-changing products to the market. Today, we are ranked top in our industry for quality and customer satisfaction. Our team’s commitment to delivering premier science and service is fueling our growth and enabling us to fulfill our mission on a larger scale—supporting more customers globally to help better the lives of the patients they serve worldwide.”
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.).
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.